sibenadet has been researched along with Cough in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jackson, D; Jones, B; Lindsey, JK; Stevens, JW | 1 |
| Byrne, N; Celli, B; Goldman, M; Halpin, D; Hepburn, R; Keating, ET | 1 |
| Jones, MK; Leidy, NK; Lloyd, J; Rocchiccioli, K; Schmier, JK | 1 |
| Calverley, P; Casty, F; Goldman, M; Keating, ET | 1 |
2 trial(s) available for sibenadet and Cough
| Article | Year |
|---|---|
Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS).
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Cough; Double-Blind Method; Dyspnea; Female; Forced Expiratory Volume; Humans; Male; Metered Dose Inhalers; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Receptors, Adrenergic, beta-2; Receptors, Dopamine D2; Sputum; Survival Analysis; Thiazoles; Treatment Outcome; Vital Capacity | 2003 |
Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale.
Topics: Adrenergic beta-Antagonists; Aged; Bronchodilator Agents; Cough; Data Collection; Dopamine Antagonists; Dyspnea; Female; Health Status Indicators; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Reproducibility of Results; Sensitivity and Specificity; Sputum; Thiazoles | 2003 |
2 other study(ies) available for sibenadet and Cough
| Article | Year |
|---|---|
Dynamic modelling of a challenge-escalation cross-over study of treatment of capsaicin-induced coughing.
Topics: Adrenergic beta-Agonists; Albuterol; Capsaicin; Cough; Cross-Over Studies; Domperidone; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Humans; Longitudinal Studies; Male; Models, Statistical; Receptors, Dopamine D2; Thiazoles | 2002 |
Conclusion. Lessons from the novel D2 dopamine receptor, beta2-adrenoceptor agonist, Viozan: chronic obstructive pulmonary disease and drug development implications.
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Cough; Drug Design; Dyspnea; Forced Expiratory Volume; Humans; Pulmonary Disease, Chronic Obstructive; Receptors, Adrenergic, beta-2; Receptors, Dopamine D2; Research Design; Sputum; Thiazoles | 2003 |